Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Cancer Discov. 2021 Feb 9;11(6):1424–1439. doi: 10.1158/2159-8290.CD-20-0564

Figure 2:

Figure 2:

Landscape of targetable genomic alterations for the LEAP Consortium Clinical Trial. Co-mutation plot showing targetable genomic alterations for the 153 patients enrolled on the LEAP trial. Samples are sorted according to the recommendation tier (across top) and grouped by drug target along left axis. For patients with more than one targetable alteration, the highest tier recommendation is used for diagram order.